New York State Psychiatric Institute
New York, 10032, United States
NCT Number: NCT00217932
The purpose of this study is to determine the effectiveness of divalproex sodium (Depakote) versus placebo in treating children with temper outbursts and severe mood disorders.
Looking for future studies?
Notify Me7 year–11 year
All sexes
Interventional
Phase 2
New York, 10032, United States
Depakote has been used to treat seizures in children for more than 20 years. The purpose of this study is to determine the effectiveness of divalproex sodium (Depakote) in treating children with temper outbursts and severe mood disorders.
This study will last 12 weeks. Participants will be randomly assigned to receive either 250 mg Depakote or placebo. The dose of medication will increase at the end of Week 1 to 500 mg of either depakote or placebo; participants will remain on this dose through Week 5. At Week 6, participants will cross-over and receive the other treatment (either depakote or placebo), which they will take through Week 12. Study visits will occur weekly and will include a physical exam, blood and urine tests, and self-reports of adverse events. In addition, caregivers will complete reports about mood swings throughout the study.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
National Institute on Drug Abuse (NIDA)
Nih
Double-Blind, Placebo-Controlled Study of Depakote (Divalproex Sodium) in Children With Temper Outbursts and Severe Mood Swings
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06282146
Anxiety Disorders, Behavior
Boston, Massachusetts, United States
View Trial DetailsNCT05680727
Behavior, Behavioral Symptoms
Boston, Massachusetts, United States
View Trial DetailsNCT05436613
Bipolar Disorder, Bipolar and Related Disorders
London, United Kingdom
View Trial DetailsNCT05078450
Anxiety Disorders, Behavior
Ann Arbor, Michigan, United States
View Trial Details